Therapy as prevention toward HCV elimination in maintenance hemodialysis: a multi-center, prospective cohort study.

"CONFLICT OF INTEREST STATEMENT M.-L.Yu.: research support from AbbVie, Abbott, BMS, Gilead, Merck and Roche. Consultant for AbbVie, Abbott, Ascletis, BMS, Gilead, J&J, Merck, Novartis, Pharmaessential and Roche. Speaker for AbbVie, Abbott, Ascletis, BMS, Gilead, Merck, Pharmaessential and Roche. C.-F.H.: speaker for AbbVie, BMS, Gilead, Merck and Roche."

"FUNDING This study was supported partly by grants from Kaohsiung Medical University (MOST 108-2314-B-037-066 -MY3, MOST 108-2314-B-037-003) and Kaohsiung Medical University Hospital [KMUH-DK(整)109005∼1, KMUH-DK(世)109002, KMUH-DK(C)110011, KMUH-DK(C)111006, KMU-DK(B)111002-1, KMUH-DK(C)110004, KMUH-DK(C)111004, KMUH-DK(B)111003-2, KMUH109-9R07]. This study was also supported in part by research grants from the Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp. (MISP#58122) and Gilead Science (IN-TW-342-5567). The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme Corp. or Gilead Science."

"Conclusions: The link-to-care project proved the concept of “treatment as prevention” by which HCV microelimination helps to prevent reinfection and new infections in the HD population.: Trial registration: ClinicalTrials.gov identifier: NCT03803410 and NCT03891550."